Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
0.724
-0.007 (-0.98%)
Real-time:   1:04PM EDT
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.71 - 0.74
52 week 0.65 - 1.05
Open 0.73
Vol / Avg. 512,854.00/591,827.00
Mkt cap 132.84M
P/E     -
Div/yield     -
EPS -0.11
Shares 179.21M
Beta 0.69
Inst. own 9%
May 13, 2015
Q1 2015 Rexahn Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 24, 2015
Rexahn Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 17, 2015
Q4 2014 Rexahn Pharmaceuticals Inc Earnings Release
Mar 9, 2015
Rexahn Pharmaceuticals Inc at ROTH Conference
Feb 10, 2015
Rexahn Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -25.33% -69.77%
Return on average equity -32.13% -94.48%
Employees 22 -
CDP Score - -

Address

Suite 455, 15245 Shady Grove Road
ROCKVILLE, MD 20850
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rexahn Pharmaceuticals, Inc. is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company�s focus is on three clinical stage drug candidates in active development, which are Archexin (Phase IIa completed); RX-3117 (Phase Ib initiated) and Supinoxin (RX-5902, Phase I trial initiated). In addition to these drug candidates, the Company has two clinical stage drug candidates for indications other than cancer: Serdaxin, for major depressive disorder; and Zoraxel, for sexual dysfunction. The Company also has three drug candidates in pre-clinical development: Archexin-Nano,for clinical benefits; RX-0047-Nano, for cancer cell survival, and RX-21101, for treatment of tumors. The Company is also working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Officers and directors

Chang H. Ahn Chairman of the Board, Chief Scientist
Age: 63
Bio & Compensation  - Reuters
Rakesh Soni President, Chief Operating Officer
Age: 59
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 44
Bio & Compensation  - Reuters
Ely Benaim Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 62
Bio & Compensation  - Reuters
Peter C. Brandt Independent Director
Age: 58
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 54
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 54
Bio & Compensation  - Reuters
Si Moon Hwang Independent Director
Age: 45
Bio & Compensation  - Reuters